1. Peer-reviewed articles published in scientific journals:

1.1 Terrasso AP, Pinto C, Serra M, Filipe A, Almeida S, Ferreira AL, et al. Novel scalable 3D cell based model for in vitro neurotoxicity testing: Combining human differentiated neurospheres with gene expression and functional endpoints. J Biotechnol 2015 Jul 10;205:82-92.
Available in: http://www.sciencedirect.com/science/article/pii/S0168165614010475

1.2 Filipe A, Almeida S, Pedroso PF, Neves R, Marques S, Sicard E, et al. Single-dose, randomized, open-Label, two-Way, crossover bioequivalence study of two formulations of pregabalin 300 mg hard capsules in healthy volunteers under fasting conditions. Drugs R D 2015 Jun;15(2):195-201.
Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488182/

1.3 Filipe A, Pedroso P, Almeida S, Neves R, Boudreault S. Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study. Drugs R D 2014 Jun;14(2):105-12.
Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070455/

1.4 Morais M, Santos PA, Mateus-Pinheiro A, Patrício P, Pinto L, Sousa N, et al. The effects of chronic stress in hippocampal adult neurogenesis and dendritic plasticity are reversed by selective MAO-A inhibition. J Psychopharmacol 2014 Dec;28(12):1178-83.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/25315831

1.5 Pedroso P, Almeida S, Filipe A, Neves RI, Boudreault S, Jiménez C. Bioequivalence studies for two different strengths of montelukast in healthy volunteers: 10 mg film-coated tablets and 5 mg chewable tablets. Drug Res (Stuttg). 2013 Sep;63(9):477-483.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/23780502

1.6 Almeida S, Pedroso P, Filipe A, Neves RI, Tanguay M, Torns A. Bioequivalence of two formulations of escitalopram. Arzneimittelforschung 2012 Jul;62(7):307-12.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/22628062

1.7 Branco JC, Tomé AM, Cruz MR, Filipe A. Pirlindole in the treatment of depression and fibromyalgia syndrome. Clin Drug Investig 2011 Oct;31(10):675-89.
Available in: http://link.springer.com/article/10.2165%2F11595410-000000000-00000

1.8 Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 2011 Jun 1;34(6):465-88.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/21585220

1.9 Almeida S, Pedroso P, Filipe A, Pinho C, Neves R, Jiménez C, et al. Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study. Arzneimittelforschung 2011;61(3):153-159.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/21528639

1.10 Almeida S, Filipe A, Neves R, Pinho C, Pedroso P, Castillo A, et al. Truncated areas under the curve in the assessment of pioglitazone bioequivalence: data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions. Arzneimittelforschung 2011;61(1):32-9.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/21355444

1.11 Macedo A, Leiria E, Filipe A. Pirlindole in the treatment of depression - a meta-analysis. Clin Drug Investig 2011;31(1):61-71.
Available in: http://link.springer.com/article/10.2165/11586690-000000000-00000/fulltext.html

1.12 Neves R, Almeida S, Filipe A, Franco Spínola AC, Abolfathi Z, Lévesque A, et al. Bioequivalence studies of two different film-coated tablet formulations of valacyclovir of two different strengths in healthy volunteers. Arzneimittelforschung 2010;60(5):273-81.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/20533765

1.13 Almeida S, Filipe A, Neves R, Desjardins I, Shink E, Castillo A. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve: a single-center, single-dose, randomized, open-label, 2-way cross-over under fasting conditions. Arzneimittelforschung 2010;60(3):116-23. Available in: http://www.ecv.de/download/download/Zeitschriften/ArzneimForsch/volltext/af_S00116-00123_33-Almeida.pdf

1.14 Almeida S, Filipe A, Neves R, Franco Spínola AC, Tanguay M, Ortuño J, et al. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects. Clin Ther 2010 Mar;32(3):556-74.
Available in: http://www.sciencedirect.com/science/article/pii/S0149291810000998

1.15 Franco Spínola AC, Almeida S, Filipe A, Neves R, Abolfathi Z, Yritia M, et al. Comparative bioavailability of two formulations of sibutramine. Int J Clin Pharmacol Ther 2009 Oct;47(10):627-37.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19825326

1.16 Franco Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clin Ther 2009 Sep;31(9):1991-2001.
Available in: http://www.sciencedirect.com/science/article/pii/S0149291809003142

1.17 Filipe A, Almeida S, Franco Spínola AC, Neves R, Tanguay M, Jiménez C, et al. Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther 2009 Mar;47(3):187-94.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19281728

1.18 Franco Spínola AC, Almeida S, Filipe A, Neves R, Tanguay M, Yritia M. Bioequivalence of two formulations of levetiracetam. Int J Clin Pharmacol Ther 2008 Nov;46(11):591-96.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/19000558

1.19 Filipe A, Almeida S, Franco Spínola AC, Neves R, Trabelsi F, Torns A, et al. Bioequivalence study of two enteric-coated formulations of pantoprazole in healthy volunteers under fed conditions. Arzneimittelforschung 2008;58(9):451-6.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/18972875

1.20 Filipe A, Almeida S, Franco Spínola AC, Trabelsi F, Ortuño J. Bioequivalence study of two letrozole tablet formulations. Single dose, randomized, open-label, 2-way crossover bioequivalence study of letrozole 2.5 mg tablets in healthy volunteers under fasting conditions. Arzneimittelforschung 2008;58(8):419-22.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/18807583

1.21 Neves R, Almeida S, Filipe A, Franco Spínola AC, Abolfathi Z, Yritia M, et al. Bioequivalence study of two different film-coated tablet formulations of losartan-hydrochlorothiazide in healthy volunteers. Arzneimittelforschung 2008;58(8):369-75.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/18807576

1.22 Tomé A, Filipe A. Farmacovigilância. Boletim do HPV. 2008 Janeiro/Março;XXI(1):13-17.

1.23 Franco Spínola AC, Almeida S, Filipe A, Tanguay M, Yritia M. Bioequivalence study of two tablet formulations of sildenafil. Arzneimittelforschung 2008;58(3):122-5.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/18488808

1.24 Almeida S, Spínola AC, Filipe A, Trabelsi F, Farré A. Truncated AUCs in the assessment of the bioequivalence of topiramate, a long half-life drug. Arzneimittelforschung 2007;57(5):249-53.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/17598694

1.25 Almeida S, Almeida A, Filipe A, Penedo C, Rocha A, Lainesse A, et al. In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. Arzneimittelforschung 2006;56(2):84-9.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/16572922

1.26 Almeida S, Filipe A, Almeida A, Antonijoan R, Garcia-Gea C, Gich I, et al. Comparative study on the bioequivalence of two different gabapentin formulations. A randomised, two-period, two-sequence, crossover clinical trial in healthy volunteers. Arzneimittelforschung 2006;56(2):59-63.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/16572918

1.27 Almeida S, Filipe A, Almeida A, Gich I, Antonijoan R, Puntes M, et al. Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. Arzneimittelforschung 2006;56(2):70-5.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/16572920

1.28 Almeida S, Filipe A, Almeida A, Wong H, Caparrós N, Tanguay M. Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomised, 2 x 2 crossover trial in healthy volunteers. Arzneimittelforschung 2005;55(7):414-9.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/16080281

1.29 Abad-Santos F, Novalbos J, Gálvez-Múgica MA, Gallego-Sandín S, Almeida S, Vallée F, et al. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res 2005 May;51(5):445-52.
Available in: http://www.sciencedirect.com/science/article/pii/S1043661804002890

1.30 Almeida S, Portolés A, Terleira A, Filipe A, Cea E, Cruz Caturla M. Comparative bioavailability/bioequivalence of two different sertraline formulations: a randomised, 2-period x 2-sequence, crossover, clinical trial in healthy volunteers. Arzneimittelforschung 2005;55(4):191-7. Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/15901041

1.31 Almeida A, Almeida S, Filipe A, Gagnon S, Mirapeix A, Girard B, et al. Bioequivalence study of two different coated tablet formulations of finasteride in healthy volunteers. Arzneimittelforschung 2005;55(4):218-22.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/15901045

1.32 Portolés A, Filipe A, Almeida S, Terleira A, Vallée F, Vargas E. Bioequivalence study of two different tablet formulations of carvedilol in healthy volunteers. Arzneimittelforschung 2005;55(4):212-7.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/15901044

1.33 Almeida S, Filipe A, Vallée F, Tanguay M, Larouche R, Lainesse A. Comparative bioavailability of two formulations of terbinafine: data from a cross-over, randomised, open-label bioequivalence study in healthy volunteers. Arzneimittelforschung 2004;54(11):757-62.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/15612617

1.34 Portolés A, Almeida S, Terleira A, de Pablo I, Filipe A, Cruz Caturla M, et al. Truncated AUC in the evaluation of fluconazole bioequivalence. A cross-over, randomised, open-label study in healthy volunteers. Arzneimittelforschung 2004;54(11):752-6.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/15612616

1.35 Portolés A, Terleira A, Almeida S, García-Arenillas M, Cruz Caturla M, Filipe A, et al. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20mg (tablets): a randomized, two-way, open-label, crossover study in healthy volunteers. Curr Ther Res Clin Exp 2004 Jan;65(1):34-46.
Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052970/

1.36 Maya M, Gonçalves N, Silva N, Filipe A, Morais J. Bioequivalence evaluation of three different oral formulations of ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2003 Apr-Jun;28(2):129-136.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/12877571

1.37 Maya M, Gonçalves N, Silva N, Filipe A, Morais J, Cruz Caturla M, et al. Comparative bioavailability of two immediate release tablets of enalapril/hydrochlorotiazide in healthy volunteers. Eur J Drug Metab Pharmacokinet 2002 Apr-Jun;27(2):91-9.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/12064377

1.38 Maya M, Domingos C, Guerreiro M, Filipe A, Morais J. Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. Eur J Drug Metab Pharmacokinet 1998 Jul-Sep;23(3):377-381.
Available in (abstract): http://www.ncbi.nlm.nih.gov/pubmed/9842980

2. Posters Presentations:

2.1 Terrasso AP, Serra M, Filipe AE, Ferreira AL, Pedroso P, Alves PM, et al. Novel human 3D cell models for neurotoxicity studies. Presented at: International Conference on Stem Cells for Drug Screening and Regenerative Medicine; 2013 Jul 19; Cantanhede, Portugal.

2.2 Franco Spínola AC, Almeida S, Filipe A, Neves R, Zohreh A, Farre A. Limitations of non-magic bullets compounds in bioequivalence assessment. How can this enhance knowledge towards the development of generic products? The Mycophenolate Mofetil Case. Ehrlich II. Presented at: 2nd World Conference on magic bullets; 2008 Oct 3-5; Nuremberg, Germany.

2.3 Almeida S, Spínola AC, Alves R, Filipe A, Trabelshi F. Body mass index in the assessment of the bioequivalence of pantoprazole formulations under fed conditions. Presented at: EUFEPS Conference on Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability; 2007 Oct 1-2; Athens, Greece.

2.4 Almeida S, Portolés A, Terleira A, Filipe A, Cea E, Cruz Caturla M. Truncated AUCs in the assessment of sertraline bioequivalence in healthy volunteers. Presented at: 3rd World Conference on Drug Absorption, Transport and Delivery: clinical significance and regulatory impact. EUFEPS; 2005 Apr 18-20; Barcelona, Spain.

2.5 Gich I, Antonijoan RM, Puntes M, Mairal E, Almeida S, Barbanoj MJ. Bioequivalencia: los diseños normativos no siempre son suficientes. Presented at: Congreso Nacional de la Sociedad Española de Farmacología Clínica; 2002 Oct 17-19; Pamplona, Spain.

3. Oral presentations:

3.1 Terrasso AP, Simão D, Pinto C, Teixeira AP, Filipe AE, Pedroso P, et al. Functional human neuron-astrocyte 3D networks for neurotoxic studies. 3D Cell Culture 2016: How close to 'in vivo' can we get? Models, applications & translation; 2016 Apr 19-21; Konzerthaus Freiburg, Germany.

3.2 Franco Spínola AC, Almeida S, Filipe A, Neves R. Highly variable drugs and highly variable drug products. Briefing on regulatory and scientific Perspectives. Presented at: EUFEPS BABP Network Open discussion: Revised European Guidelines on Bioequivalence; 2009 Jan 14-15; Bonn, Germany.

3.3 Sampedro A, Terleira A, Almeida S, Cea E, Portolés A. Estudio de bioequivalencia de dos formulaciones de carvedilol en dosis única (25 mg), en voluntarios sanos. Libro de Resúmenes del XIX Congreso de la Sociedad Española de Farmacología Clínica, 2004.